Rhumbline Advisers Outlook Therapeutics, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.2 - $1.78 $96 - $854	-480 Reduced 0.25%	193,831 $42,000
Q2 2023 Aug 08, 2023	BUY	$1.02 - $1.89 $16,289 - $30,183	15,970 Added 8.95%	194,311 $338,000
Q1 2023 May 11, 2023	BUY	$1.0 - $1.35 $32,849 - $44,346	32,849 Added 22.58%	178,341 $194,000
Q4 2022 Feb 14, 2023	SELL	$0.87 - $1.33 $158 - $242	-182 Reduced 0.12%	145,492 $157,000
Q3 2022 Nov 10, 2022	BUY	$1.02 - $1.26 $10,404 - $12,852	10,200 Added 7.53%	145,674 $178,000
Q2 2022 Aug 11, 2022	BUY	$0.91 - $2.01 $38,984 - $86,108	42,840 Added 46.25%	135,474 $138,000
Q1 2022 May 12, 2022	BUY	$1.22 - $2.03 $54,538 - $90,749	44,704 Added 93.27%	92,634 $165,000
Q4 2021 Feb 10, 2022	SELL	$1.27 - $2.23 $2,627 - $4,613	-2,069 Reduced 4.14%	47,930 $65,000
Q3 2021 Nov 12, 2021	BUY	$2.12 - $2.76 $8,507 - $11,075	4,013 Added 8.73%	49,999 $108,000
Q2 2021 Aug 05, 2021	BUY	$1.78 - $2.76 $81,855 - $126,921	45,986 New	45,986 $115,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.